脾照射与胃癌辅助放化疗后≥3级淋巴细胞减少相关
该研究分析2015年1月至2020年12月接受辅助放化疗的84例胃癌患者,中位随访42个月。结果显示脾平均剂量>40 Gy与放化疗后严重淋巴细胞减少相关,而严重淋巴细胞减少是总生存和复发无生存较差的危险因素,且感染累积发生率更高。作者认为优化脾剂量体积直方图参数可能降低严重淋巴细胞减少风险。
要点
- 脾平均剂量>40 Gy与放化疗后严重淋巴细胞减少的 odds 升高相关(OR 1.13,95%CI 1.01-1.26,P=0.041)。
- 放化疗后严重淋巴细胞减少是总生存较差的危险因素(HR 2.47,95%CI 1.24-4.92,P=0.010)。
- 严重淋巴细胞减少患者感染累积发生率更高(2.53,95%CI 1.03-6.23,P=0.043)。
核心结论
- 高脾照射剂量增加胃癌辅助放化疗后严重淋巴细胞减少的 odds,后者是总生存较低、复发和感染风险较高的独立预测因素。
- 作者认为优化脾剂量体积直方图参数可能降低放化疗后严重淋巴细胞减少的风险。
研究设计与样本
- 分析2015年1月至2020年12月接受胃癌辅助放化疗的患者,共84例,中位随访42个月。
- 记录脾剂量体积直方图参数(脾平均剂量MSD及接受至少×Gy的脾体积百分比)和放化疗前后外周血计数。
- 采用多变量逻辑回归评估放化疗后严重淋巴细胞减少(CTCAE 5.0版≥3级,绝对淋巴细胞计数<0.5 K/μL)的相关因素。
- 采用Cox模型或竞争风险分析评估总生存、无复发生存和感染事件累积发生率。
主要发现
- 放化疗前中位绝对淋巴细胞计数为1.8 K/μL(范围0.9-3.1 K/μL),放化疗后为0.9 K/μL(范围0.0-4.9 K/μL),P<0.001。
- 脾平均剂量>40 Gy与严重放化疗后淋巴细胞减少相关(OR 1.13,95%CI 1.01-1.26,P=0.041)。
- 男性相对女性的OR为0.25(95%CI 0.09-0.70,P=0.008),基线绝对中性粒细胞计数每增加1单位的OR为1.61(95%CI 1.02-2.58,P=0.040),均与严重放化疗后淋巴细胞减少相关。
- 严重放化疗后淋巴细胞减少是总生存较差的危险因素(HR 2.47,95%CI 1.24-4.92,P=0.010),也是无复发生存较差的危险因素(HR 2.27,95%CI 1.16-4.46,P=0.017)。
- 严重放化疗后淋巴细胞减少患者感染累积发生率更高(2.53,95%CI 1.03-6.23,P=0.043)。
关键数值与推荐
- 严重放化疗后淋巴细胞减少定义为CTCAE 5.0版≥3级,绝对淋巴细胞计数<0.5 K/μL。
- 脾平均剂量>40 Gy与严重放化疗后淋巴细胞减少相关(OR 1.13,95%CI 1.01-1.26,P=0.041)。
- 严重放化疗后淋巴细胞减少与总生存较差相关(HR 2.47,95%CI 1.24-4.92,P=0.010)。
- 严重放化疗后淋巴细胞减少与无复发生存较差相关(HR 2.27,95%CI 1.16-4.46,P=0.017)。
- 严重放化疗后淋巴细胞减少患者感染累积发生率更高(2.53,95%CI 1.03-6.23,P=0.043)。
临床怎么用
- 作者认为优化脾剂量体积直方图参数可能降低放化疗后严重淋巴细胞减少的风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Adjuvant chemoradiation therapy (CRT) in gastric cancer inevitably results in an unintentional spleen radiation dose. We aimed to determine the association between the spleen radiation dose and the observed severity of lymphopenia which may affect the clinical outcomes (survival time and infection risk). METHODS: Patients who received adjuvant CRT for gastric cancer between January 2015 and December 2020 were analyzed. The splenic dose-volume histogram (DVH) parameters were reported as mean splenic dose (MSD) and percentage of splenic volume receiving at least × Gray (Gy). Peripheral blood counts were recorded pre- and post-CRT. The development of severe (Common Terminology Criteria for Adverse Events, version 5.0, grade ≥ 3) post-CRT lymphopenia (absolute lymphocyte count [ALC] < 0.5 K/μL) was assessed by multivariable logistic regression using patient and dosimetric factors. Overall survival (OS), recurrence-free survival (RFS), and cumulative incidence of infectious events were estimated and analyzed using the Cox model or competing risk analysis. RESULTS: Eighty-four patients with a median follow-up duration of 42 months were analyzed. Pre- and post-CRT median ALC values were 1.8 K/μL (0.9-3.1 K/μL) and 0.9 K/μL (0.0-4.9 K/μL), respectively (P < 0.001). MSD > 40 Gy (odds ratio [OR], 1.13; 95 % confidence interval [CI], 1.01-1.26; P = 0.041), sex (OR for male to female, 0.25; 95 % CI, 0.09-0.70; P = 0.008), and baseline absolute neutrophil count (OR per 1 unit increase, 1.61; 95 % CI, 1.02-2.58; P = 0.040) were associated with the development of severe post-CRT lymphopenia, which was a risk factor for poorer OS (hazard ratio [HR] = 2.47; 95 % CI, 1.24-4.92; P = 0.010) and RFS (HR = 2.27; 95 % CI, 1.16-4.46; P = 0.017). The cumulative incidence of infections was higher among severe post-CRT lymphopenia patients (2.53, 95 % CI, 1.03-6.23, P = 0.043). CONCLUSION: High splenic radiation doses increase the odds of severe post-CRT lymphopenia, an independent predictor of lower OS and higher risks of recurrence and infections in gastric cancer patients receiving adjuvant CRT. Therefore, optimizing the splenic DVH parameters may decrease the risk of severe post-CRT lymphopenia.
引用
- Lee SF, Yip PL, Wong A, et al. Splenic irradiation contributes to grade ≥ 3 lymphopenia after adjuvant chemoradiation for stomach cancer. Clin Transl Radiat Oncol. 2022. PMID: 35909437. doi:10.1016/j.ctro.2022.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。